Q4 2017

Well Informed

With 2017 winding down, we're taking stock of how we performed throughout the year and setting goals for 2018. Towards that end, we recently distributed our annual Client Satisfaction Surveys and we look forward to hearing back from all of you about how we're doing and where we need to make improvements.

This edition of the Well Informed newsletter features articles about our WellManaged – Diabetes program, our success with managing Hepatitis C treatment costs, staff achievements, and more.

We appreciate your business and hope you find this information interesting and beneficial. As always, please let us know if you have any questions or concerns.

Sincerely,
Zach Johnson, President, WellDyneRx

INTRODUCING:
WellManaged - Diabetes

WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter



To raise awareness about diabetes and healthy living, WellDyneRx is proudly participating in American Diabetes Month®. Observed every November, American Diabetes Month is an important element in the American Diabetes Association's efforts to

American Diabetes Association®
AMERICAN DIABETES MONTH®

focus our nation's attention on the disease and the tens of millions of people affected by it. Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes - more than 30 million people - and another 84 million adults are at a high risk of developing it.

Diabetes is also the leading cost driver for WellDyneRx clients, accounting for more than 10% of total drug expenditures, and these numbers are continuing to rise as the disease spreads. As the most expensive therapeutic class in terms of traditional drug spend, diabetes medications cost more than specialty medications for oncology, multiple sclerosis, and HIV. Additionally, medication adherence rates for diabetes therapy tend to be poor, and overall hemoglobin A1c levels do not appear to be trending downward despite increases in associated drug treatment costs.

To help our clients provide quality care while containing costs, WellDyneRx offers a comprehensive diabetes management program, called WellManaged – Diabetes, that increases medication adherence rates through patient education; reduces plan spend through aggressive formulary management; and improves outcomes through monitoring of key measures. Program participants can take advantage of one-on-one

(Continues on next page)

(Continued from prvious page)

access to dedicated US Specialty Care (USSC) diabetes pharmacists and Certified Diabetes Educators (CDEs).The program also fosters care coordination by reaching out to providers to alert them about medication non-adherence and to ensure each patient is receiving the most cost-effective and clinically appropriate treatment.

Participants in the WellManaged - Diabetes program with Case Management achieve the highest medication adherence rates and optimal therapeutic outcomes, which drives down total healthcare costs for our clients. This program identifies at-risk members based on their level of diabetes control and/or other risk factors, such as complexity of drug regimen, adherence rate(s), and gaps in care. Case management sessions are conducted using telehealth technology, either via telephone or via HIPAA-compliant video chat.

WellManaged – Diabetes program through USSC offers your members:

- **Informative newsletters to help them manage their diabetes**
- **Additional educational resources and access to diabetes experts**
- **Ongoing communications from the USSC Clinical Care Team**

Additionally, all WellDyneRx plan participants are eligible to receive a free OneTouch System glucose meter! Monitoring blood sugar levels is a critical component of any successful diabetes treatment plan. We want to optimize every member's health by tracking this important information. To receive their free meters, instruct plan participants to visit www.OneTouch.orderpoints.com and enter order code number 739WDRX01. Alternatively, they may call 1-888-883-7091 and provide order code number 739WDRX01.

Members can also visit www.cornerstones4care.com for additional education about diabetes.

For more information about WellManaged — Diabetes, contact your Account Manager.

UPCOMING & Conferences Tradeshows

We are currently developing our 2018 conference and tradeshow calendar. If you would like us to consider attending a specific industry event, please **let us know.**

Implementation of Indication-Based Hepatitis C Formulary Results in Greater Access to Care and Lower Drug Costs

According to the Centers for Disease Control and Prevention (CDC), about 3.5 million Americans are currently living with the hepatitis C virus (HCV) and roughly half are unaware of their infection. HCV is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC), as well as the most common indication for liver transplantation in many countries. In the United States, about 70% of individuals infected with HCV have genotype 1, 16% have genotype 2, 12% have genotype 3, and less than 1% have genotypes 4 through 7.

Once diagnosed, patients can take advantage of new, highly effective treatments, known as direct-acting antivirals (DAA), that cure the vast majority of infections within two to three months. This is in stark contrast to the standard HCV treatment prior to 2011 (a combination of interferon and ribavirin), which required 24 to 48 weeks of therapy and yielded significantly lower cure rates. While newer medications have transformed the treatment of HCV, they come with high price tags. Gilead's Harvoni®, for example, costs approximately $94,500 per patient for 12 weeks of therapy, and the Viekira Pak™, manufactured by AbbieVie Inc., costs approximately $83,000 per patient for the same duration of treatment.

WellDyneRx was the first pharmacy benefit manager in the country to adopt a Hepatitis C indication-based formulary using Zepatier as our preferred product for patients with genotypes 1 and 4. When Merck & Co. Inc., the manufacturer of Zepatier, set its list price at $54,600 for a 12 week regimen, our clinicians immediately recognized the significant cost-saving opportunities. This price is 34% lower than the Viekira Pak and 42% lower than Harvoni. Additionally, the clinical outcomes for patients using Zepatier were proven to be equivalent – or better – than higher cost medications in the same therapeutic class.

Zepatier was adopted by WellDyneRx as the preferred agent for patients with genotypes 1 and 4 in January 2017. When clinicians compared claims from the first six months of 2016 (1H16) with the first six months of 2017 (1H17), they found a substantial 36% increase in the percentage of patients approved for treatment following the implementation of the indication-based HCV formulary. Significantly, during this same time period (1H17), total drug costs decreased by 35%. **This translates into huge savings for our clients in that, for every 100 HCV patients treated, total drug spend could be reduced by $3.35 million.**

Indication-Based Hepatitis C Formulary	Average Cost to Treat Each Patient
1H16 - Pre-Implementation	$96,621
1H17 - Post-Implementation	$63,070
Average Savings Per Patient	$33,551

For more information about the WellDyneRx Indication-Based formulary, contact your Account Manager.

US Specialty Care Pharmacists Receive Prestigious Certifications

US Specialty Care, WellDyneRx's industry-leading specialty pharmacy, is proud to announce that Marlette Oelofsen, Pharmacist in Charge, earned the prestigious Certified Specialty Pharmacist (CSPT) distinction. Ms. Oelofsen becomes one of only 229 Certified Specialty Pharmacists in the country to achieve this honor.

Presented by the Specialty Pharmacy Certification Board (SPCB), this credential certifies a pharmacist is an expert in specialty pharmaceuticals used to treat complex chronic illnesses. Requirements to obtain this credential are rigorous: a minimum of 3,000 hours of specialty pharmacy practice, education and passing an exam created by a diverse group of subject matter experts. The CSP exam is developed using ongoing processes that meet national standards, and is based on scientific analysis of job tasks and required knowledge.

Additionally, two US Specialty Care pharmacists, , Dipali Kadiwar, and Courtney Luster, and three WellDyneRx pharmacists, Patty Taddei-Allen, Jeenal Patel, and Beth Johnson, recently became board certified in geriatric pharmacy (BCGP). Geriatric pharmacists provide pharmaceutical care to the elderly, including wellness, treatment, monitoring and patient safety services. These pharmacists have the advanced knowledge and experience to focus on the special needs of older patients who may have concurrent illnesses and take multiple medications.

The staff at US Specialty Care is committed to excellence - and it shows. The pharmacy won the inaugural Specialty Pharmacy Patient Choice Award (based on nationwide feedback from specialty patients) in May, 2017. "After winning the inaugural Specialty Pharmacy Patient Choice Award, these certifications are yet another example of our staff's commitment to providing outstanding service to both our clients and our patients," said Nick Page, PharmD, Vice President. "These certifications highlight our ongoing commitment to education, best-in-class pharmacy operations, and optimal patient care."

NEW FDA-APPROVED DRUGS

BRAND NAME	GENERIC NAME(S)	THERAPEUTIC USE	BRIEF DESCRIPTION	POTENTIAL IMPACT
Baxdela™ (Melinta Therapeutics)	delafloxacin meglumine	Antibiotic	Baxdela™ is a fluoroquinolone antibacterial indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The recommended dosing is 450 mg orally or 300 mg intravenous (IV) infusion every 12 hours for 5 to 14 days. Baxdela is available in 450 mg tablets and 300 mg single-dose vials.	High
Bevyxxa® (Portola Pharmaceuticals)	betrixaban maleate	VTE prophylaxis	Bevyxxa® is an oral Factor Xa inhibitor indicated for the prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. The recommended dose is 160 mg once, followed by 80 mg orally once daily for 35 to 42 days. Dosage should be decreased to 40 mg daily for patients with renal impairment. Bevyxxa is available in 40 mg and 80 mg capsules..	Low
Nerlynx™ (Puma Biotechnology)	neratinib	Breast cancer	Nerlynx™ is a kinase inhibitor indicated for the extended adjuvant treatment of adults with early stage HER2-overexpressed/ amplified breast cancer, to follow adjuvant trastuzumab (Herceptin)-based therapy. The recommended dose is 240 mg (6 tablets) orally once daily with food, continuously for one year and is available in 40 mg tablets. This is the first drug to be FDA-approved for long-term adjuvant breast cancer treatment; however, the adverse effects of severe diarrhea and liver toxicity may limit its use.	Moderate

BRAND NAME	GENERIC NAME(S)	THERAPEUTIC USE	BRIEF DESCRIPTION	POTENTIAL IMPACT
Vosevi™ (Gilead Sciences, Inc.)	sofosbuvir; velpatasvir; voxilaprevir	Chronic hepatitis C	Vosevi™ is a direct-acting antiviral (DAA) indicated for treatment of chronic hepatitis C (HCV) infection (genotypes 1, 2, 3, 4, 5, and 6) in treatment-experienced (TE) adult patients with prior exposure to a NS5A inhibitor containing regimen. Additionally, Vosevi is approved for treatment of HCV in TE adults with genotypes 1a and 3 with prior exposure to a sofosbuvir containing regimen that DID NOT include an NS5A inhibitor. Both indications include adults without cirrhosis or with compensated cirrhosis. The recommended dose is one tablet orally daily for 12 weeks and it comes in a fixed combination tablet containing sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100 mg.	High
Tremfya™ (Janssen Biotech, Inc.)	guselkumabc	Plaque psoriasis	Tremfya™ is an interleukin-23 (IL-23) blocker indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya was approved based on clinical trials demonstrating improved skin clearance compared to placebo, Humira® (adalimumab) and Stelara® (ustekinumab). The recommended dose is 100 mg subcutaneously (SC) at Week 0 and Week 4 followed by 100 mg SC every 8 weeks thereafter. It is supplied in a single-dose 100 mg/mL prefilled syringe.	High
Idhifa™ (Celgene Corporation)	enasidenib mesylate	Acute myeloid leukemia (AML)	Idhifa™ is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-a (IDH2) mutation as detected	Moderate

(Continues on next page)

BRAND NAME	GENERIC NAME(S)	THERAPEUTIC USE	BRIEF DESCRIPTION	POTENTIAL IMPACT
Idhifa™ (Celgene Corporation	enasidenib mesylate	Acute myeloid leukemia (AML)	*(Continued from previous page)* by an FDA-approved test. The recommended dose is 100 mg orally daily with or without food until disease progression or unacceptable toxicity. This medication has a black box warning for differentiation syndrome which can be fatal if not treated. Idhifa is available in a 50 mg and 100 mg tablet.	Moderate
Mavyret™ (AbbVie)	glecaprevir; pibrentasvir	Chronic hepatitis C	Mavyret™ is a direct-acting antiviral (DAA) indicated for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, and 6 without cirrhosis or with compensated cirrhosis. Additionally, this medication is indicated for the treatment of adults with genotype 1 infection who have previously been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both. The recommended dose is three tablets orally daily for up to 8 to 16 weeks depending on diagnosis. This is the first DAA approved for 8-weeks of treatment for all genotypes and is available in a fixed-combination tablet containing glecaprevir 300 mg and pibrentasivr 120 mg.	High
Vabomere™ (The Medicines Company)	meropenum; vaborbactam	Antibiotic	Vabomere™ is an antibacterial indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by susceptible bacteria. Vabomere is a combination medication containing a currently approved antibiotic; meropenem, with a *(Continues on next page)*	High

BRAND NAME	GENERIC NAME(S)	THERAPEUTIC USE	BRIEF DESCRIPTION	POTENTIAL IMPACT
Vabomere™ (The Medicines Company)	meropenum; vaborbactam	Antibiotic	*(Continued from previous page)* new beta-lactamase inhibitor; vaborbactam. The recommended dose is 4 grams administered every 8 hours by intravenous (IV) infusion over 3 hours for up to 14 days. Dosage adjustment is necessary for patients with renal impairment. It is available in single-dose vials containing 1 gram of meropenem and 1 gram of vaborbactam.	High
Besponsa™ (Wyeth Pharmaceuticals)	Inotuzumab ozogamicin	Acute lymphoblastic leukemia (ALL)	Besponsa™ is a CD22-directed antibody indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphocytic leukemia (ALL). Both the first cycle and subsequent cycles are dosed based on patient's body surface area (BSA) and continued until disease progression or toxicity. Besponsa contains a boxed warning concerning the increased risk of severe liver damage, including veno-occlusive disease (VOD). This medication is available in 0.9 mg lyophilized powder single-dose vials for reconstitution.	Moderate
Aliqopa™ (Bayer HealthCare Pharmaceuticals)	copanlisib	Relapsed follicular lymphoma (rFL)	Aliqopa™ is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. The recommended dose is 60 mg administered as a one-hour intravenous (IV) infusion on Days 1, 8 and 15 of a 28-day treatment cycle and continued until disease progression or unacceptable toxicity. Aliqopa is available in 60 mg single-dose vials.	Moderate

BRAND NAME	GENERIC NAME(S)	THERAPEUTIC USE	BRIEF DESCRIPTION	POTENTIAL IMPACT
Verzenio™ (Eli Lilly)	abemaciclib	Breast cancer	Verzenio™ is a kinase inhibitor indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Additionally, Verzenio is indicated as monotherapy for treatment of adult patients with HR (+), HER2 (-) advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. The recommended starting dose in combination with fulvestrant is 150 mg orally twice daily and as monotherapy is 200 mg orally twice daily. It is available in 50, 100, 150 and 200 mg tablets.	High